SCHEMBL7674520

SCHEMBL7674520

Cc1c2c(n(C)c1C(=O)c1ccc(C#N)cc1)C(C)C(=O)O2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34
GAA P10253 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
EGLN1 Q9GZT9 2/20 0.32
GSK3B P49841 3/20 0.32
GSK3A P49840 1/20 0.32
VNN1 O95497 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
MAPK14 Q16539 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7682237 0.86 ALDH1A1 (0.40) ALDH1A1GAARAB9AMEN1KMT2A
SCHEMBL7681373 0.85 ALDH1A1 (0.34) ALDH1A1CA1CA2CA12CA9
SCHEMBL7675834 0.84 ABCB11 (0.41) ALDH1A1MEN1KMT2A
SCHEMBL7682007 0.84 MAPT (0.38) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL7674713 0.81 GRM2 (0.39) ALDH1A1CA1CA2CA12CA9
SCHEMBL7677930 0.76 ALDH1A1 (0.34) ALDH1A1PKMCA1CA2CA12
SCHEMBL7680382 0.75 ALDH1A1 (0.38) ALDH1A1CA1CA2
SCHEMBL7675526 0.69 ABCB11 (0.42) ALDH1A1GAAMEN1KMT2A
SCHEMBL7678745 0.68 ALDH1A1 (0.36) ALDH1A1RAB9AMEN1KMT2A
SCHEMBL7677989 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885PKM 4613/4885CA1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.